About Vannsh Life Sciences
Vannsh Life Sciences is a company based in Hyderabad (India) founded in 2009. It operates as a B2B and Manufacturing. The company has 64 employees. Vannsh Life Sciences offers products and services including Bendamustine Hydrochloride, Bortezomib, Capecitabine, Dasatinib, and Erlotinib Hydrochloride. Vannsh Life Sciences operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Hyderabad, India
- Employees 64
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vannshlifesciences.com
- Social LinkedIn X Facebook
- Legal Name Vannsh Life Sciences Private Limited
- Date of Incorporation 16 Jul, 2014
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹50.34 Cr
FY 2024 · +13% YoY
- Net Profit₹56.6 Lakh
FY 2024 · 1% margin
- EBITDA₹6.21 Cr
FY 2024 · 12% margin
- Employee Count64
Associated legal entities of Vannsh Life Sciences
Vannsh Life Sciences operates through Vannsh Life Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vannsh Life Sciences Private Limited CIN U24100TG2014PTC094869 | Active | 16 Jul 2014 | Hyderabad, Telangana | ₹50.3 Cr | 64 | 4 | View details |
Products & Services of Vannsh Life Sciences
Vannsh Life Sciences offers a comprehensive portfolio of products and services, including Bendamustine Hydrochloride, Bortezomib, Capecitabine, Dasatinib, and Erlotinib Hydrochloride.
Anti-cancer API used for treating lymphomas and leukemias.
Proteasome inhibitor for multiple myeloma and mantle cell lymphoma.
Oral chemotherapeutic agent for metastatic breast and colorectal cancers.
Tyrosine kinase inhibitor for chronic myeloid leukemia treatment.
Targeted therapy for non-small cell lung and pancreatic cancers.
Nucleoside analog for treating various solid tumors.
Tyrosine kinase inhibitor for chronic myeloid leukemia.
Antimetabolite used in cancer and autoimmune disease treatments.
Board of directors of Vannsh Life Sciences Private Limited (Vannsh Life Sciences)
Vannsh Life Sciences Private Limited is the primary company behind Vannsh Life Sciences. The board of Vannsh Life Sciences Private Limited currently have 3 directors; the longest-serving is Venkateswarreddy Sandadi, appointed in 2014. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Venkateswarreddy Sandadi DIN 03126101 | Director | 16 Jul 2014 | 12 yrs 2 mo | Vannsh Life Sciences Private Limited |
| Sridevi Sandadi DIN 06755312 | Director | 16 Jul 2014 | 12 yrs 2 mo | Vannsh Life Sciences Private Limited |
| Bidyut Roy DIN 08741647 | Director | 01 Jul 2023 | 3 yrs 3 mo | Vannsh Life Sciences Private Limited |
Financials of Vannsh Life Sciences
Figures of Vannsh Life Sciences Private Limited, the primary company behind Vannsh Life Sciences, for FY 2024. Revenue was ₹50.34 Cr (+13% year on year). Net profit was ₹56.6 Lakh (1% margin). EBITDA was ₹6.21 Cr (12% margin). Revenue has grown at a compounded annual rate of +44% over three years and +137% over five years.
- ₹50.34 CrRevenue · FY 2024 · +13% YoY
- ₹56.6 LakhNet profit · 1% margin
- ₹6.21 CrEBITDA · 12% margin
- ₹21.43 CrPaid-up capital
- 64Employees (provident fund records)
- +44%Revenue CAGR, 3 years
- +137%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Vannsh Life Sciences Private Limited are on its company page.
Detailed financial statements for Vannsh Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Vannsh Life Sciences
Vannsh Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Vannsh Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vannsh Life Sciences
The website of Vannsh Life Sciences (vannshlifesciences.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Vannsh Life Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Vannsh Life Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Vannsh Life Sciences
10 companies that operate in the same segment as Vannsh Life Sciences (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vannsh Life Sciences
Vannsh Life Sciences was founded in 2009.
Vannsh Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Vannsh Life Sciences has 64 employees.
The primary company behind Vannsh Life Sciences, Vannsh Life Sciences Private Limited, reported revenue of ₹50.34 Cr for FY 2024, up 13% year on year.
Vannsh Life Sciences is a specialty pharmaceutical company incorporated in 2014 under Indian Companies Act, focusing on research, development, and manufacturing of high-quality APIs and intermediates. It operates facilities in Hyderabad and Visakhapatnam, India, with capabilities in synthetic chemistry and drug delivery technologies. The company supplies to leading generic firms worldwide, emphasizing quality standards and timely delivery, while maintaining regulatory compliance and innovation in healthcare products.
Vannsh Life Sciences's top competitors include Merck, Roivant Sciences and AbbVie.
Vannsh Life Sciences offers Bendamustine Hydrochloride, Bortezomib, Capecitabine, Dasatinib, and 4 more products and services.
Vannsh Life Sciences operates through Vannsh Life Sciences Private Limited.
The legal entities of Vannsh Life Sciences currently have 4 directors, including Venkateswarreddy Sandadi, Bidyut Roy, Anuradha Nemalikanty and others.
The website of Vannsh Life Sciences receives about 681 thousand visits a month.